Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Myasthaenia"'
Publikováno v:
BJA Open, Vol 4, Iss , Pp 100092- (2022)
Background: Using neuromuscular blocking drugs (NMBDs) for patients with myasthaenia gravis remains a challenge in perioperative management. Sugammadex has enabled the safe use of NMBDs. We investigated whether the adverse outcomes, and the treatment
Externí odkaz:
https://doaj.org/article/e387c4711e0146638dfdf556bf5b1b53
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jose Carrion-Rojas, Esteban Alberto Plasencia-Dueñas, Sofia Pilar Ildefonso-Najarro, Marcio José Concepción-Zavaleta, Cesar Joel Benites-Moya
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-6 (2020)
Endocrinology, Diabetes & Metabolism Case Reports
ESSALUD-Institucional
Seguro Social de Salud
instacron:ESSALUD
Endocrinology, Diabetes & Metabolism Case Reports
ESSALUD-Institucional
Seguro Social de Salud
instacron:ESSALUD
El síndrome de Cushing es un trastorno endocrino que causa infertilidad anovulatoria secundaria a hipercortisolismo; por lo tanto, el embarazo rara vez ocurre durante su curso. Presentamos el caso de una mujer de 24 años, gestante de 16 semanas, co
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2020)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2020)
Summary Sodium/glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycaemic agents that are increasingly used in the management of type 2 diabetes mellitus (T2DM). They are now recommended as second-line pharmacotherapy (in conjunction wi
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2020)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2020)
Summary We present three cases of acute diabetic neuropathy and highlight a potentially underappreciated link between tightening of glycaemic control and acute neuropathies in patients with diabetes. Case 1: A 56-year-old male with poorly controlled
Autor:
Daad Alotaibi, Waleed Al-Ghamdi, Seham Alzahrani, Afshan Masood, Aishah Ekhzaimy, Muhammad Mujammami
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2020)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2020)
Summary Central diabetes insipidus (CDI) and several endocrine disorders previously classified as idiopathic are now considered to be of an autoimmune etiology. Dermatomyositis (DM), a rare autoimmune condition characterized by inflammatory myopathy
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2017)
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports
Summary Parathyroid carcinoma is an extremely rare endocrine malignancy that accounts for less than 1% of cases of primary hyperparathyroidism. We report a 44-year-old woman who presented with fatigue and diffuse bone pain. Laboratory findings reveal
Autor:
Alessandro Brancatella, Giulia Di Dalmazi, Daniele Sgrò, Nicola Viola, Patrizio Caturegli, Mirco Cosottini, Isabella Lupi, Claudio Marcocci, Giulia Lanzolla, Francesco Latrofa
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-6 (2019)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-6 (2019)
Summary Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen 4/B7 (CTLA-4/B7) pathways are key regulators in T-cell activation and tolerance. Nivolumab, pembrolizumab (PD-1 inhibitors)
Autor:
Arslan Butt, Aiden Devitt, Francis M. Finucane, Lisa Reddington, Mohammed Faraz Rafey, Barry Coffey, David W.P. Lappin
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2019)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2019)
We describe two cases of SGLT2i-induced euglycaemic diabetic ketoacidosis, which took longer than we anticipated to treat despite initiation of our DKA protocol. Both patients had an unequivocal diagnosis of type 2 diabetes, had poor glycaemic contro
Autor:
Laia Casamitjana Espuña, Ismael Capel, Assumpta Caixàs, Jose León Mengíbar, Mercedes Rigla, Isabel Mazarico, Teresa Bonfill
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2019)
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-4 (2019)
Summary Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias. Durvalumab use is asso